Foghorn Therapeutics
FHTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +14.4% in FY2025
Adrian Gottschalk is the CEO of Foghorn Therapeutics and was paid $2.4M in FY2025 (Dec), up 51%.
Pay$100 in the stock at the end of FY21 → $24
Executives3
See all- 1Adrian GottschalkPresident and Chief Executive OfficerFY2025
- 2Steven Bellon, Ph.D..Chief Science OfficerFY2025
- 3Alfonso Quintás-CardamaChief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allFoghorn Therapeutics paid its 3 named executives $4.7M in total in FY2025 (Dec). CEO Adrian Gottschalk was paid $2.4M of that.
| Name | |||
|---|---|---|---|
| Adrian GottschalkPresident and Chief Executive Officer | |||
| Steven Bellon, Ph.D..Chief Science Officer | |||
| Alfonso Quintás-CardamaChief Medical Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Foghorn Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Michael MendelsohnDirector · 8 yr on the boardIndependentCompensation—Paid as an executive
- Scott BillerDirector · 5 yr on the boardIndependent—Paid as an executive
- Ian F. SmithDirector · 4 yr on the boardIndependentCompensation—Paid as an executive
- Thomas J. Lynch, Jr.Director · 3 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Neil GallagherDirector · 0 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 11, 2026 | FY2025 |
| Proxy statement | DEF 14A | May 5, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 3, 2024 | FY2023 |
| Annual report | 10-K | Mar 7, 2024 | FY2023 |
